A new drug developed by Foresee Pharmaceuticals Co (逸達生技) to treat acute respiratory distress syndrome in COVID-19 patients has received approval from an independent data monitoring committee (IDMC) in the US.
In a filing with the Taiwan Stock Exchange on Monday, Foresee said that it had received a positive recommendation from an IDMC phase 2 safety review meeting to continue its phase 2/3 clinical trial of FP-025, a drug being developed to treat asthma and severe COVID-19 cases who have acute respiratory distress syndrome.
An IDMC is a group of experts external to a study that reviews cumulative data and treatment efficacy data and monitors patient safety in an ongoing clinical trial.
There is no medication available at present to treat acute respiratory distress syndrome and lung fibrosis, and if successfully developed, FP-025 would be a first-in-class therapy for the syndrome, Foresee said.
The phase 2 trial is part of a randomized, double-blind, placebo-controlled, multi-center phase 2/3 study, the company said.
An interim analysis is planned at the end of the phase 2 trial, and based on the results of the analysis, the trial may proceed to phase 3 with potential modifications to the research protocol, it said.
Approximately 99 people are taking part in the trial in the US, and the efficacy results are expected in the fourth quarter of this year.
The company would also assess the possibility of conducting trials in Taiwan, India and some Central and South American countries, Foresee said.
About 3 to 17 percent of COVID-19 cases develop acute respiratory distress syndrome, the company said, citing US Centers for Disease Control data.
Among those who are hospitalized, that number increases to 20 to 42 percent and to 67 to 85 percent for those admitted to intensive care, it said.
Before the COVID-19 outbreak, acute respiratory distress syndrome affected approximately 200,000 people a year in the US, resulting in nearly 75,000 deaths annually, and it accounts for 10 percent of intensive care unit admissions globally, the company said.
Foresee’s FP-025 is described as a highly selective inhibitor of matrix metalloproteinase-12, which has been identified as a component in causing pulmonary injury and fibrotic conditions in the lungs of COVID-19 patients.
It is a promising treatment for inflammatory airway diseases, the company said.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last